KTN Launches UK Medicines Manufacturing Landscape Portal
The portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK.
The Knowledge Transfer Network (KTN), the United Kingdom’s innovation network, announced the launch of a new web portal that outlines the UK’s strengths and capabilities in medicines manufacturing.
KTN’s Medicines Manufacturing Landscape portal is an interactive tool that pulls together the innovation landscape, company base, and manufacturing sites for the entire medicines sector in the UK. The platform was developed by KTN on behalf of the Medicines Manufacturing Industry Partnership (MMIP) to address confusion about medicines manufacturing activities in the UK.
The MMIP was jointly established by the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) and includes partners such as Actavis (Allergan plc), AstraZeneca, Eisai, Fujifilm Diosynth Biotechnologies, GlaxoSmithKline, KTN, ReNeuron, and Pfizer. This partnership was formed to strengthen collaboration between the industry and the government in making the UK an attractive and innovation-driven country for medicines manufacturing.
Source: KTN
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
August 5th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
